Influence of pegvisomant on serum ghrelin and leptin levels in acromegalic patients

European Journal of Endocrinology

Volumn 163, Issue 5, 2010, Pages 727-734

  Roemmler, J ^a   Otto, B ^a   Arafat, A M ^b   Bidlingmaier, M ^a   Schopohl, J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; GLUCOSE; GROWTH HORMONE; INSULIN; LEPTIN; PEGVISOMANT; BIOLOGICAL MARKER; DRUG DERIVATIVE; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE;

ACROMEGALY; ACTH SECRETING CELL; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; GROWTH HORMONE BLOOD LEVEL; HUMAN; IMMUNOFLUORESCENCE; INSULIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGED; BLOOD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DRUG ANTAGONISM; MIDDLE AGED;

ACROMEGALY; ADULT; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; GHRELIN; HUMAN GROWTH HORMONE; HUMANS; LEPTIN; MALE; MIDDLE AGED; RECEPTORS, SOMATOTROPIN;

EID: 77957842588     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0344     Document Type: Article

References (48)

1. Kopchick JJ, Parkinson C, Stevens EC & Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocrine Reviews 2002 23 623-646. (doi:10.1210/er.2001-0022) (Pubitemid 35191626)
2. Janssen JA, Van Der Toorn FM, Hofland LJ, Van Koetsveld P, Broglio F, Ghigo E, Lamberts SW & Jan Van Der Lely A. Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy. European Journal of Endocrinology 2001 145 711-716. (doi:10.1530/eje.0.1450711) (Pubitemid 33133677)
3. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC & Bennett WF. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. Journal of Clinical Endocrinology and Metabolism 1999 84 2098-2103. (doi:10.1210/jc.84.6.2098) (Pubitemid 30647040)
4. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B & Strasburger CJ. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology 2007 156 75-82. (doi:10.1530/eje.1.02312) (Pubitemid 46553905)
5. Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G & Trainer PJ. Pegvisomant interference in GH assays results in underestimation of GH levels. European Journal of Endocrinology 2007 156 315-319. (doi:10.1530/eje.1.02341) (Pubitemid 46554499)
6. Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z & Strasburger CJ. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. Journal of Clinical Endocrinology and Metabolism 2001 86 3304-3310. (doi:10.1210/jc.86.7. 3304) (Pubitemid 32673502)
7. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP & Trainer PJ. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. European Journal of Endocrinology 2003 149 521-527. (doi:10.1530/eje.0.1490521)
8. Lindberg-Larsen R, Moller N, Schmitz O, Nielsen S, Andersen M, Orskov H & Jorgensen JO. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2007 92 1724-1728. (doi:10.1210/jc.2006-2276) (Pubitemid 46997178)
9. Higham CE, Rowles S, Russell-Jones D, Umpleby AM & Trainer PJ. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2009 94 2459-2463. (doi:10.1210/jc.2008-2086)
10. Moller L, Norrelund H, Jessen N, Flyvbjerg A, Pedersen SB, Gaylinn BD, Liu J, Thorner MO, Moller N & Lunde Jorgensen JO. Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects. Journal of Clinical Endocrinology and Metabolism 2009 94 4524-4532. (doi:10.1210/jc.2009-0381)
11. Plockinger U & Reuter T. Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study. European Journal of Endocrinology 2008 158 467-471. (doi:10.1530/EJE-07-0637)
12. Goto K, Doessing S, Nielsen RH, Flyvbjerg A & Kjaer M. Growth hormone receptor antagonist treatment reduces exercise performance in young males. Journal of Clinical Endocrinology and Metabolism 2009 94 3265-3272. (doi:10.1210/jc.2009-0407)
13. Hamann A & Matthaei S. Regulation of energy balance by leptin. Experimental and Clinical Endocrinology & Diabetes 1996 104 293-300. (doi:10.1055/s-0029-1211457)
14. Horvath TL, Diano S, Sotonyi P, Heiman M & Tschop M. Minireview: ghrelin and the regulation of energy balance - a hypothalamic perspective. Endocrinology 2001 142 4163-4169. (doi:10.1210/en.142.10.4163)
15. Woods SC, Schwartz MW, Baskin DG & Seeley RJ. Food intake and the regulation of body weight. Annual Review of Psychology 2000 51 255-277. (doi:10.1146/annurev.psych.51.1.255)
16. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K & Matsukura S. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. Journal of Clinical Endocrinology and Metabolism 2002 87 240-244. (doi:10.1210/jc.87.1.240)
17. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E & Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001 50 707-709. (doi:10.2337/diabetes.50.4.707) (Pubitemid 32242624)
18. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K & Nakazato M. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000 141 4255-4261. (doi:10.1210/en.141.11.4255)
19. Otto B, Spranger J, Benoit SC, Clegg DJ & Tschop MH. The many faces of ghrelin: new perspectives for nutrition research? British Journal of Nutrition 2005 93 765-771. (doi:10.1079/BJN20051446)
20. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, Mori K, Komatsu Y, Usui T, Shimatsu A, Ogawa Y, Hosoda K, Akamizu T, Kojima M, Kangawa K & Nakao K. Ghrelin strongly stimulates growth hormone release in humans. Journal of Clinical Endocrinology and Metabolism 2000 85 4908-4911. (doi:10.1210/jc.85.12.4908)
21. Cappiello V, Ronchi C, Morpurgo PS, Epaminonda P, Arosio M, Beck-Peccoz P & Spada A. Circulating ghrelin levels in basal conditions and during glucose tolerance test in acromegalic patients. European Journal of Endocrinology 2002 147 189-194. (doi:10.1530/eje.0.1470189)
22. Kawamata T, Inui A, Hosoda H, Kangawa K & Hori T. Perioperative plasma active and total ghrelin levels are reduced in acromegaly when compared with in nonfunctioning pituitary tumours even after normalization of serum GH. Clinical Endocrinology 2007 67 140-144. (doi:10.1111/j.1365-2265.2007.02851.x) (Pubitemid 46955454)
23. Jarkovska Z, Rosicka M, Marek J, Hana V, Weiss V, Justova V, Lacinova Z, Haluzik M & Krsek M. Plasma levels of total and active ghrelin in acromegaly and growth hormone deficiency. Physiological Research 2006 55 175-181.
24. Eden Engstrom B, Burman P, Holdstock C & Karlsson FA. Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. Journal of Clinical Endocrinology and Metabolism 2003 88 5193-5198. (doi:10.1210/jc.2003-030713)
25. Tschop M, Flora DB, Mayer JP & Heiman ML. Hypophysectomy prevents ghrelin-induced adiposity and increases gastric ghrelin secretion in rats. Obesity Research 2002 10 991-999. (doi:10.1038/oby.2002.135)
26. Freda PU, Reyes CM, Conwell IM, Sundeen RE & Wardlaw SL. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy. Journal of Clinical Endocrinology and Metabolism 2003 88 2037-2044. (doi:10.1210/jc.2002-021683)
27. Kozakowski J, Rabijewski M & Zgliczynski W. Decrease in serum ghrelin levels in patients with acromegaly normalize after successful surgical treatment. Endokrynologia Polska 2005 56 862-870.
28. Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H & Tanaka T. Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. Journal of Clinical Endocrinology and Metabolism 1998 83 3476-3479. (doi:10.1210/jc.83.10.3476)
29. Damjanovic SS, Petakov MS, Raicevic S, Micic D, Marinkovic J, Dieguez C, Casanueva FF & Popovic V. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. Journal of Clinical Endocrinology and Metabolism 2000 85 147-154. (doi:10.1210/jc.85.1.147) (Pubitemid 32268805)
30. Tan KC, Tso AW & Lam KS. Effect of Sandostatin LAR on serum leptin levels in patients with acromegaly. Clinical Endocrinology 2001 54 31-35. (doi:10.1046/j.1365-2265.2001.01180.x)
31. Popovic V, Damjanovic S, Dieguez C & Casanueva FF. Leptin and the pituitary. Pituitary 2001 4 7-14. (doi:10.1023/A:1012938308654)
32. Muller AF, Lamberts SW, Janssen JA, Hofland LJ, Koetsveld PV, Bidlingmaier M, Strasburger CJ, Ghigo E & Van Der Lely AJ. Ghrelin drives GH secretion during fasting in man. European Journal of Endocrinology 2002 146 203-207. (doi:10.1530/eje.0.1460203) (Pubitemid 34162912)
33. Parkinson C, Whatmore AJ, Yates AP, Drake WM, Brabant G, Clayton PE & Trainer PJ. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly. Clinical Endocrinology 2003 59 168-174. (doi:10.1046/j.1365-2265.2003.01795.x)
34. Wu Z, Bidlingmaier M, Liu C, De Souza EB, Tschop M, Morrison KM & Strasburger CJ. Quantification of the soluble leptin receptor in human blood by ligand-mediated immunofunctional assay. Journal of Clinical Endocrinology and Metabolism 2002 87 2931-2939. (doi:10.1210/jc.87.6.2931)
35. Bristow AF, Gooding RP & Das RE. The International Reference Reagent for insulin-like growth factor-I. Journal of Endocrinology 1990 125 191-197. (doi:10.1677/joe.0.1250191)
36. Roemmler J, Otto B, Steffin B, Bidlingmaier M & Schopohl J. Serum leptin and ghrelin levels in active and inactive acromegalic patients during an oral glucose tolerance test. Experimental and Clinical Endocrinology & Diabetes 2009 117 135-141. (doi:10.1055/s-2008-1078739)
37. Giavoli C, Cappiello V, Corbetta S, Ronchi CL, Morpurgo PS, Ferrante E, Beck-Peccoz P & Spada A. Different effects of short- and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults. Clinical Endocrinology 2004 61 81-87. (doi:10.1111/j.1365-2265.2004. 02067.x) (Pubitemid 38951649)
38. Malik IA, English PJ, Ghatei MA, Bloom SR, Macfarlane IA & Wilding JP. The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency. Clinical Endocrinology 2004 60 137-141. (doi:10.1111/j.1365-2265.2004.01929.x)
39. Tong J, Tschop MH, Aulinger BA, Davis HW, Yang Q, Liu J, Gaylinn BD, Thorner MO, D'alessio D & Tso P. The intestinal lymph fistula model - a novel approach to study ghrelin secretion. American Journal of Physiology. Gastrointestinal and Liver Physiology 2010 298 G474-G480. (doi:10.1152/ajpgi. 00367.2009)
40. Kim SW, Kim KW, Shin CS, Park Do J, Park KS, Cho BY, Lee HK & Kim SY. Acylated ghrelin secretion is acutely suppressed by oral glucose load or insulin-induced hypoglycemia independently of basal growth hormone secretion in humans. Hormone Research 2007 67 211-219. (doi:10.1159/000097098)
41. Lucidi P, Murdolo G, Di Loreto C, Parlanti N, De Cicco A, Ranchelli A, Fatone C, Taglioni C, Fanelli C, Santeusanio F & De Feo P. Meal intake similarly reduces circulating concentrations of octanoyl and total ghrelin in humans. Journal of Endocrinological Investigation 2004 27 RC12-RC15.
42. Gormsen LC, Nielsen C, Gjedsted J, Gjedde S, Vestergaard ET, Christiansen JS, Jorgensen JO & Moller N. Effects of free fatty acids, growth hormone and growth hormone receptor blockade on serum ghrelin levels in humans. Clinical Endocrinology 2007 66 641-645. (doi:10.1111/j.1365-2265.2007.02786.x)
43. Soriano-Guillen L, Barrios V, Martos G, Chowen JA, Campos-Barros A & Argente J. Effect of oral glucose administration on ghrelin levels in obese children. European Journal of Endocrinology 2004 151 119-121. (doi:10.1530/eje.0.1510119)
44. Caixas A, Bashore C, Nash W, Pi-Sunyer F & Laferrere B. Insulin, unlike food intake, does not suppress ghrelin in human subjects. Journal of Clinical Endocrinology and Metabolism 2002 87 1902. (doi:10.1210/jc.87.4.1902)
45. Bolanowski M, Milewicz A, Bidzinska B, Jedrzejuk D, Daroszewski J & Mikulski E. Serum leptin levels in acromegaly - a significant role for adipose tissue and fasting insulin/glucose ratio. Medical Science Monitor 2002 8 CR685-CR689. (Pubitemid 35257332)
46. Grottoli S, Gasco V, Mainolfi A, Beccuti G, Corneli G, Aimaretti G, Dieguez C, Casanueva F & Ghigo E. Growth hormone/insulin-like growth factor I axis, glucose metabolism, and lypolisis but not leptin showsome degree of refractoriness to short-termfasting inacromegaly. Journal of Endocrinological Investigation 2008 31 1103-1109.
47. Lloyd RV, Jin L, Tsumanuma I, Vidal S, Kovacs K, Horvath E, Scheithauer BW, Couce ME & Burguera B. Leptin and leptin receptor in anterior pituitary function. Pituitary 2001 4 33-47. (doi:10.1023/A:1012982626401)
48. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H & Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999 402 656-660. (doi:10.1038/45230)